Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.52 |
| ▸ | MGAM | O43451 | 7/20 | 0.52 |
| ▸ | AMY1A | P0DUB6 | 7/20 | 0.52 |
| ▸ | SI | P14410 | 7/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14294674 | 0.82 | SLC9A1 (0.53) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL17103124 | 0.81 | SLC9A1 (0.51) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL13875211 | 0.81 | GAA (0.55) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL19911444 | 0.79 | SLC9A1 (0.56) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL19911474 | 0.78 | NAMPT (0.49) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL19848282 | 0.78 | GAA (0.51) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL19911491 | 0.78 | POLB (0.43) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL19911452 | 0.78 | GRM2 (0.63) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL19911453 | 0.77 | GAA (0.48) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL19915729 | 0.77 | GAA (0.48) | GAAMGAMAMY1ASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-0114675-A2 | Color photographic silver halide light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | GAA 4140/4885MGAM 3479/4885AMY1A 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.